# US 2010/0168206 A1 · GNAQ Targeted dsRNA Compositions And Methods For Inhibiting Expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168206 A1
- Document ID: US20100168206A1
- Status: Published application
- Kind: A1
- Application number: 12/635,630
- Filed: 2009-12-10
- Published: 2010-07-01
- Earliest claimed: 2008-12-10
- Assignees: Alnylam Pharmaceuticals, Inc.
- Inventors: Jared Gollob; Gregory Hinkle; Ivanka Toudjarska; David Bumcrot
- Web page: https://patentgrep.com/patent/US20100168206A1

## CPC

- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61P 17/00: Drugs for dermatological disorders
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/1138: {against receptors or cell surface proteins}
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/321: 2'-O-R Modification
- C12N 2310/335: Modified T or U
- C12N 2310/344: Position-specific modifications, e.g. on every purine, at the 3'-end
- C12N 2310/3515: Lipophilic moiety, e.g. cholesterol
- C12N 2320/31: Combination therapy
- C12N 2320/51: modulating the chemical stability, e.g. nuclease-resistance
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, and methods of using the dsRNA to inhibit expression of GNAQ.

## Claims

### Claim 1

A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of a G-alpha q subunit (GNAQ) of a heterotrimeric G gene, comprising a sense strand and an antisense strand comprising a region of complementarity complementary to an mRNA encoding GNAQ, wherein each strand is at least 15 nucleotides in length.

### Claim 2 (depends on 1)

The dsRNA of claim 1, wherein the sense strand consists of SEQ ID NO:1579 and the antisense strand consists of SEQ ID NO:1580.

### Claim 3 (depends on 1)

The dsRNA of claim 1, wherein the antisense strand is complementary to at least 15 contiguous nucleotides of SEQ ID NO:1421.

### Claim 4 (depends on 1)

The dsRNA of claim 1, wherein the antisense strand is complementary to at least the first 11 nucleotides of SEQ ID NO:1421.

### Claim 5 (depends on 1)

The dsRNA of claim 1, wherein the sense strand comprises 15 or more contiguous nucleotides of SEQ ID NO:1421 or SEQ ID NO:1579.

### Claim 6 (depends on 1)

The dsRNA of claim 1, wherein the antisense strand comprises 15 or more contiguous nucleotides of SEQ ID NO:1422 or SEQ ID NO:1580.

### Claim 7 (depends on 1)

The dsRNA of claim 1, wherein the sense strand sequence comprises SEQ ID NO:1421 and the antisense strand sequence comprises of SEQ ID NO:1422.

### Claim 8 (depends on 1)

The dsRNA of claim 1, wherein administration of 0.1 nM of the dsRNA to a A375 cell results in about 66% inhibition of GNAQ mRNA expression as measured by a real time PCR assay or administration of 1 nM of the dsRNA to a A375 cell results in about 61% inhibition of GNAQ mRNA expression as measured by a real time PCR assay or administration of 1 nM of the dsRNA to a A579 cell results in about 82% inhibition of GNAQ mRNA expression as measured by a real time PCR assay or administration of 10 nM of the dsRNA to a OMM1.3 cell results in about 42% inhibition of GNAQ mRNA expression as measured by a real time PCR assay or administration of the dsRNA to a UMEL202 cell results in about 81% inhibition of GNAQ mRNA expression as measured by a real time PCR assay.

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

(canceled)

### Claim 15

(canceled)

### Claim 16

(canceled)

### Claim 17

(canceled)

### Claim 18

(canceled)

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

(canceled)

### Claim 28

(canceled)

### Claim 29

(canceled)

### Claim 30 (depends on 1)

The dsRNA of claim 1, wherein the region of complementary is at least 15 nucleotides in length.

### Claim 31 (depends on 30)

The dsRNA of claim 30, wherein the region of complementarity is between 19 and 21 nucleotides in length.

### Claim 32 (depends on 30)

The dsRNA of claim 30, wherein the region of complementarity is 19 nucleotides in length.

### Claim 33

(canceled)

### Claim 34

(canceled)

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37

(canceled)

### Claim 38 (depends on 1)

The dsRNA of claim 1, wherein each strand is no more than 30 nucleotides in length.

### Claim 39 (depends on 1)

The dsRNA of claim 1, wherein at least one strand comprises a 3′ overhang of at least 1 nucleotide.

### Claim 40 (depends on 1)

The dsRNA of claim 1, wherein each strand comprises a 3′ overhang consisting of 2 nucleotides.

### Claim 41 (depends on 1)

The dsRNA of claim 1, wherein each strand comprises a 3′ overhang consisting of dTdT.

### Claim 42 (depends on 1)

The dsRNA of claim 1, comprising a modification that causes the dsRNA to have increased stability in a biological sample.

### Claim 43 (depends on 1)

The dsRNA of claim 1, wherein said dsRNA comprises at least one modified nucleotide.

### Claim 44 (depends on 42)

The dsRNA of claim 42, wherein said modified nucleotide is selected from the group of: a 2′-O-methyl modified nucleotide, a nucleotide comprising a 5′-phosphorothioate group, and a terminal nucleotide linked to a cholesteryl derivative or dodecanoic acid bisdecylamide group.

### Claim 45 (depends on 42)

The dsRNA of claim 42, wherein said modified nucleotide is chosen from the group of: a 2′-deoxy-2′-fluoro modified nucleotide, a 2′-deoxy-modified nucleotide, a locked nucleotide, an abasic nucleotide, 2′-amino-modified nucleotide, 2′-alkyl-modified nucleotide, morpholino nucleotide, a phosphoramidate, and a non-natural base comprising nucleotide.

### Claim 46 (depends on 42)

The dsRNA of claim 42, comprising at least one 2′-O-methyl modified nucleotide and at least one 2′-deoxythymidine-3′-phosphate nucleotide comprising a 5′-phosphorothioate group.

### Claim 47 (depends on 42)

The dsRNA of claim 42, wherein the sense strand comprises all 2′-O-methyl modified pyrimidines and the antisense strand comprises 2′-O-methyl modified pyrimidines when the pyrimidine is adjacent to A and each strand comprises dTdT at the 3′ end.

### Claim 48 (depends on 42)

The dsRNA of claim 42, wherein the sense strand comprises all 2′-O-methyl modified pyrimidines and the antisense strand comprises 2′-O-methyl modified pyrimidines when the pyrimidine is adjacent to A and each strand comprises dTsdT at the 3′ end.

### Claim 49 (depends on 42)

The dsRNA of claim 42, wherein the sense strand comprises all 2′-O-methyl modified pyrimidines and the antisense strand comprises 2′-O-methyl modified pyrimidines when a) the pyrimidine is adjacent to A or b) the pyrimidine is a uracil adjacent to a U or a G, and each strand comprises dTsdT at the 3′ end.

### Claim 50 (depends on 1)

The dsRNA of claim 1, further comprising a ligand.

### Claim 51 (depends on 50)

The dsRNA of claim 50, wherein the ligand is conjugated to the 3′-end of the sense strand of the dsRNA.

### Claim 52 (depends on 1)

A composition for inhibiting expression of a GNAQ gene comprising the dsRNA of claim 1 and pharmaceutical formulation.

### Claim 53 (depends on 52)

The composition of claim 52, wherein the pharmaceutical formulation is a lipid formulation.

### Claim 54 (depends on 52)

The composition of claim 52, wherein the pharmaceutical formulation is a LNP formulation, a LNP01 formulation, a XTC-SNALP formulation, a SNALP formulation, or a LNP11 formulation.

### Claim 55 (depends on 1)

An isolated cell containing the dsRNA of claim 1.

### Claim 56 (depends on 1)

A vector comprising a nucleotide sequence that encodes at least one strand of the dsRNA of claim 1.

### Claim 57 (depends on 56)

A cell comprising the vector of claim 56.

### Claim 58 (depends on 1)

The dsRNA of claim 1, wherein said dsRNA, upon contact with a cell expressing said GNAQ, inhibits expression of said GNAQ gene by at least 40% compared to a cell not so contacted.

### Claim 59 (depends on 1)

The dsRNA of claim 1, wherein the dsRNA has an 1050 of less than 10 pM.

### Claim 60 (depends on 1)

A method of inhibiting GNAQ expression in a cell, the method comprising:
(a) introducing into the cell the dsRNA of claim 1; and
(b) maintaining the cell produced in step (a) for a time sufficient to obtain degradation of the mRNA transcript of a GNAQ gene, thereby inhibiting expression of the GNAQ gene in the cell.

### Claim 61

(canceled)

### Claim 62 (depends on 1)

A method of treating a disorder mediated by GNAQ expression comprising administering to a human in need of such treatment a therapeutically effective amount of the dsRNA of claim 1.

### Claim 63 (depends on 62)

The method of claim 62, wherein the human has uveal melanoma, cutaneous melanoma, Blue nevi, Nevi of Ota, a small lung tumor, or a neuroendocrine tumors.

### Claim 64

(canceled)

### Claim 65

(canceled)
